¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå ±Ô¸ð : ¿ë·®º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ª ¹üÀ§º° ¹× ¿¹Ãø
Global Large Volume Parenteral (LVP) Market Size By Volume (100 ml - 250 ml, 250 ml - 500 ml), By Application (Therapeutic Injections, Fluid Balance Injections), By End-User (Hospitals, Medical Centres), By Geographic Scope And Forecast
»óǰÄÚµå
:
1738592
¸®¼Ä¡»ç
:
Verified Market Research
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 202 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå ±Ô¸ð´Â 2024³â 130¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2026-2032³â 8.88%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 257¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ȯÀÚ¿¡°Ô ¾à¹°À» º¸´Ù ¾ÈÀüÇÏ°í ½Å¼ÓÇϰí È¿°úÀûÀ¸·Î Åõ¿©ÇÒ ¼ö ÀÖ´Â ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é¼ ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚµéÀº ÇöÀç ¸¸¼º ÁúȯÀ» Ä¡·áÇϱâ À§ÇØ ¹é½ÅÀ̳ª ¾à¹°À» ´Üȸ Åõ¿©ÇÏ´Â °ÍÀ» ¼±È£Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå º¸°í¼´Â ½ÃÀåÀÇ Àü¹ÝÀûÀÎ Æò°¡¸¦ ´ã°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ºÎ¹®, µ¿Çâ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, °æÀï ±¸µµ, ½ÃÀå¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¿äÀÎ µîÀ» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÕ´Ï´Ù.
¼¼°è ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀåÀÇ Á¤ÀÇ
ºñ°æ±¸Á¦´Â ÁÖ»çÁ¦À̸ç, ü³» ÁÖ»ç, ÁÖÀÔ, À̽Ŀ¡ ÀÇÇÑ Åõ¿©¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â ¹«±Õ Á¦Ç°ÀÔ´Ï´Ù. ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP)´Â 100ml ÀÌ»óÀÇ ´ÜÀ§ ¿ë·® ¿ë±â¸¦ ¸»Çϸç, °¡¿¿¡ ÀÇÇØ ÃÖÁ¾ÀûÀ¸·Î ¸ê±ÕµË´Ï´Ù. ÀÌ·¯ÇÑ ºñ°æ±¸¿ë ÀǾàǰÀº 100ml ¶Ç´Â ±× ÀÌ»óÀÇ Å©±âÀÇ ºÀÁö³ª º´¿¡ ´ã°Ü ÆÇ¸ÅµÇ´Â ¸µ°Å¾à¿¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ´ë·®À¸·Î ÇÊ¿äÇÑ °æ¿ì ´ë·®À¸·Î Æ÷ÀåµË´Ï´Ù. ºñ°æ±¸¿ë ÀǾàǰÀ» Á¦Á¶ÇÏ´Â °æ¿ì, ºñ°æ±¸¿ë ÀǾàǰÀº ¸ê±ÕµÈ °íü Á¦Á¦ ¶Ç´Â ¹ß¿ÀÌ ¾ø´Â ¾×ü Á¦Á¦À̸ç, 1ȸºÐ ¶Ç´Â ´ÙȸºÐ ¿ë±â¿¡ ¹Ú½º Æ÷ÀåµÈ ÇÑ À¯Çü ÀÌ»óÀÇ À¯È¿ ¼ººÐÀ» ÇÔÀ¯Çϰí ÀÖ½À´Ï´Ù.
ºñ°æ±¸ ¾à¹°Àº ÁÖÀÔ, ÀÌ½Ä ¶Ç´Â ü³» ÁÖ»ç·Î Åõ¿©µË´Ï´Ù. À̵éÀº ¹°¸®Àû, ÈÇÐÀû, »ý¹°ÇÐÀû ¿À¿°ÀÌ ¾ø½À´Ï´Ù. »ý¸í°øÇÐ ºÐ¾ßÀÇ ¹ßÀü°ú ÇÔ²² °æ±¸ Åõ¿©°¡ ÀûÇÕÇÏÁö ¾ÊÀº °æ¿ì ºñ°æ±¸ Åõ¿©°¡ °¡Àå ÀûÇÕÇϱ⠶§¹®¿¡ ºñ°æ±¸ Åõ¿©µÇ´Â ¾à¹°ÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ºñ°æ±¸ ¾à¹°Àº ÃÖ´ë È¿´É°ú »ý¹°ÇÐÀû ÀÌ¿ë °¡´É¼ºÀ» Á¦°øÇϸç, ¸¹Àº °æ¿ì °æ±¸ Åõ¿©º¸´Ù ºñ°æ±¸ Åõ¿©¸¦ ¼±È£ÇÕ´Ï´Ù.
¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå °³¿ä
°Ç° °ü·Ã ¹®Á¦ Áõ°¡´Â »ç¶÷µéÀÇ ÀÔ¿øÀ² Áõ°¡·Î À̾îÁ® ´õ ºü¸£°í, ´õ ¾ÈÀüÇϰí, ´õ È¿°úÀûÀÎ ¾à¹° Åõ¿©¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼¼°è ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¼ö¼ú °Ç¼ö´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ ´õ ºü¸¥ ¾à¹° Åõ¿© °æ·Î¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¹é½Å°ú ¾à¹°ÀÇ 1ȸ Åõ¿©¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ¼ö¿ä Áõ°¡¿¡ µû¶ó ÇöÁö Á¦Á¶°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾à¹°ÀÇ ´ëºÎºÐÀÌ ¼ÒȰüÀ» ¿ìȸÇÏ¿© ¼øÈ¯ Áß¿¡ Á÷Á¢ Èí¼öµÇ±â ¶§¹®¿¡ Á¤È®ÇÑ Åõ¾à·®À» Á¦°øÇÔÀ¸·Î½á Åõ¾à¿¡ µµ¿òÀÌ µË´Ï´Ù. ¸¸¼ºÁúȯ ¹× ±âŸ »ýȰ½À°üº´ ȯÀÚ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ ÀÔ¿øÇϴ ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
½Å°æ°è Áúȯ, Á¾¾çÇÐ, ´ç´¢º´¿¡ ´ëÇÑ ´ÜÀÏ ¿ë·®ÀÇ µµÀÔÀº ¼¼°è °í¿ë·® ºñ°æ±¸(LVP) ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ȯÀÚµéÀº ÇöÀç ¸¸¼º ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ ¹é½Å°ú ¾à¹°ÀÇ 1ȸ Åõ¿©¸¦ ¼±È£Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¼ö¿ä Áõ°¡¿Í Á¦Á¶ Áö¿¬ÀÌ °áÇÕÇÏ¿© ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, LVPÀÇ Ç°Áú ¹®Á¦ ¹× ±âŸ Á¦Á¶»óÀÇ ¹®Á¦·Î ÀÎÇØ ºñ°æ±¸¿ë ¾àǰÀÌ ºÎÁ·ÇÏ¿© ½ÃÀåÀ» ¾ïÁ¦ÇÕ´Ï´Ù.
¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀåÀº ¿ë·®, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªÀ» ±âÁØÀ¸·Î ¼¼ºÐȵ˴ϴÙ.
´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå,¿ë·®º°
- 100-250ml
- 250-500ml
- 500-1,000ml
- 1,000-2,000ml
- 2,000ml ÀÌ»ó
¿ë·®Àº 100-250ml, 250-500ml, 500-1,000ml, 1,000-2,000ml, 2,000ml ÀÌ»óÀ¸·Î ³ª´µ¸ç, 2022³â¿¡´Â 250ml-500mlÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ºÎ¹®ÀÌ ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP)´Â ÈçÈ÷ LVP·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ºñ°æ±¸ÀûÀ¸·Î Àü´ÞµÇ´Â 250ml ÀÌ»óÀÇ ¹«±Õ Á¦Á¦ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, °¡Àå ³Î¸® »ç¿ëµÇ´Â LVP´Â 0.9% ¿°È³ªÆ®·ý, 5% Æ÷µµ´ç ÇÔÀ¯ »ý¸®½Ä¿°¼ö(D5NS), 5% Æ÷µµ´ç ÇÔÀ¯ ¼ö¿ë¾×(D5W), Á¥»ê ¸µ°Ö¾×(L.R.¾×)°ú °°Àº Ç¥ÁØ/¿°±â¼º ¿ë¾×À¸·Î ¸¸µé¾îÁø Á¤¸Æ ³» ¿ë¾×ÀÔ´Ï´Ù. 1L)ÀÇ ¹é ¶Ç´Â º´À¸·Î Á¦°øµÇ´Â Á¤¸ÆÁÖ»ç ¿ë¾×ÀÔ´Ï´Ù.
´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå,¿ëµµº°
- Ä¡·á¿ë ÁÖ»çÁ¦
- ü¾× ±ÕÇü ÁÖ»ç
- ¿µ¾çÁÖ»ç
¿ëµµº°·Î´Â Ä¡·á¿ë ÁÖ»çÁ¦, ü¾× ±ÕÇü ÁÖ»çÁ¦, ¿µ¾ç ÁÖ»çÁ¦·Î ±¸ºÐµË´Ï´Ù. ¿ëµµº°·Î´Â ¿µ¾ç Áֻ簡 ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â ³ëÀÎ ¹× ¼Ò¾Æ Àα¸ÀÇ »ç¿ë Áõ°¡, ±Ë¾ç¼º ´ëÀå¿° ¹× ¾Ï°ú °°Àº ¸¸¼º Áúȯ °ü¸®¿¡ ´ëÇÑ ¿ä±¸ »çÇ× ¶§¹®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚµéÀº ¿µ¾ç ºÎÁ·À» º¸ÃæÇϱâ À§ÇØ Áö¼ÓÀûÀÎ ¿µ¾ç º¸Ãæ ½Ã½ºÅÛÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ ÀÌ ºÎ¹®À» ÁÖµµÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå,ÃÖÁ¾ »ç¿ëÀÚº°
ÃÖÁ¾ »ç¿ëÀÚº°·Î ½ÃÀåÀº º´¿ø, ÀÇ·á¼¾ÅÍ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀåÀº º´¿ø°ú ÀÇ·á½Ã¼³ÀÌ Àüü ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù.
´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå,Áö¿ªº°
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Áö¿ªº° ºÐ¼®¿¡¼ ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«·Î ºÐ·ùµË´Ï´Ù. ºÏ¹Ì´Â °ø°ø ¹× ¹Î°£ ±â°üÀÇ ÇコÄÉ¾î ¿¬±¸¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ, ±â¼úÀûÀ¸·Î °¡Àå Áøº¸µÈ ÀÇ·á±â±â, ±ÔÁ¦ ±â°ü°ú »ê¾÷ ¹× ´ëÇаúÀÇ ±ä¹ÐÇÑ ÆÄÆ®³Ê½ÊÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
- ¶ÇÇÑ, À¯¸®ÇÑ °áÁ¦ ±ÔÁ¤À¸·Î ÀÎÇØ ÀÔ¿ø ȯÀÚ ¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ ºÎ¹®ÀÇ ÀÌ¿ë·üÀÌ ³ô¾ÆÁú °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¤¸Æ¿µ¾ç¿¡ ´ëÇÑ È¯±Þ »óȲÀº ±àÁ¤ÀûÀÔ´Ï´Ù. ¸ÞµðÄɾî´Â ¹Ì±¹ ³» ºñ°æ±¸ ¹× °æÀ念¾ç °ü·Ã ºñ¿ëÀÇ ÃÖ´ë 80%(ÀÇ·á¿ëǰ, ÀÇ»ç Áø·á, ±âŸ °ü·Ã ÀÇ·á ¼ºñ½º ºñ¿ë Æ÷ÇÔ)¸¦ ȯÀÚ¿¡°Ô º¸»óÇϰí ÀÖ½À´Ï´Ù.
ÁÖ¿ä ÁøÃâ ±â¾÷
¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå Á¶»ç º¸°í¼´Â ¼¼°è ½ÃÀå¿¡ ÃÊÁ¡À» ¸ÂÃá ±ÍÁßÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ½ÃÀå ÁÖ¿ä ±â¾÷À¸·Î´Â B. Braun Melsungen AG, Fresenius Kabi AG, BML Parenteral Drugs, Pfizer, Inc, Otsuka Pharmaceuticals, Kelun Pharma, Cook Pharma, Patheon, BAG Healthcare, Southwest Pharmaceuticals, Beximco Pharma, Baxter Healthcare Corporation µîÀÌ ÀÖ½À´Ï´Ù.
´ç»ç ½ÃÀå ºÐ¼®¿¡´Â ÀÌ·¯ÇÑ ÁÖ¿ä ±â¾÷¸¸À» ´Ù·ç´Â ¼½¼ÇÀÌ ÀÖÀ¸¸ç, ¾Ö³Î¸®½ºÆ®°¡ Á¦Ç° º¥Ä¡¸¶Å· ¹× SWOT ºÐ¼®°ú ÇÔ²² ¸ðµç ÁÖ¿ä ±â¾÷ÀÇ À繫 Á¦Ç¥¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. °æÀï ±¸µµ ¼½¼Ç¿¡´Â À§ÀÇ ¼¼°è ÁøÃâ±â¾÷ÀÇ ÁÖ¿ä °³¹ß Àü·«, ½ÃÀå Á¡À¯À² ¹× ½ÃÀå ¼øÀ§ ºÐ¼®µµ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.
- ¿¡À̽º ¸ÅÆ®¸¯½º ºÐ¼®
- º» º¸°í¼¿¡¼ Á¦°øÇÏ´Â ¿¡À̽º ¸ÅÆ®¸¯½º¿¡¼´Â ¼ºñ½ºÀÇ Æ¯Â¡°ú Çõ½Å¼º, È®À强, ¼ºñ½º Çõ½Å¼º, »ê¾÷ Ä¿¹ö¸®Áö, »ê¾÷ µµ´Þ ¹üÀ§, ¼ºÀå ·Îµå¸Ê µî ´Ù¾çÇÑ ¿äÀÎÀ» ¹ÙÅÁÀ¸·Î ÀÌ »ê¾÷°ú °ü·ÃµÈ ÁÖ¿ä ±â¾÷ÀÇ ¼øÀ§¸¦ °ÔÀçÇϰí ÀÖÀ¸¹Ç·Î, ÀÌ »ê¾÷°ú °ü·ÃµÈ ÁÖ¿ä ±â¾÷ÀÇ ¼º°ú¸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù. ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀ» ¹ÙÅÁÀ¸·Î °¢ ±â¾÷À» ¾×Ƽºê, Ä¿ÆÃ ¿§Áö, À̸Ó¡, À̸Ó¡, À̳뺣ÀÌÅÍÀÇ ³× °¡Áö ¹üÁÖ·Î ºÐ·ùÇÏ¿© ¼øÀ§¸¦ ¸Å°å½À´Ï´Ù.
- ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀåÀÇ ¿¡À̽º ¸ÅÆ®¸¯½º ºÐ¼®
- ½ÃÀåÀÇ ¸Å·Â
- Á¦°øµÇ´Â ½ÃÀå ¸Å·ÂÀÇ À̹ÌÁö´Â ¼¼°è ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä Áö¿ª¿¡ ´ëÇÑ Á¤º¸¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù. ¿ì¸®´Â ÁöÁ¤µÈ Áö¿ªÀÇ »ê¾÷ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿µÇâ¿äÀÎÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.
- ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå Áö¸®Àû Ç¥½Ã
- Porter's Five Forces
- Porter's Five Forces´Â °æÀï»çÀÇ Çൿ°ú °¢ »ê¾÷¿¡¼ÀÇ Àü·«Àû Æ÷Áö¼Å´×À» ÀÌÇØÇÒ ¼ö Àִ û»çÁøÀ» Á¦°øÇÏ´Â ÇÁ·¹ÀÓ¿öÅ©ÀÔ´Ï´Ù. Porter's Five Forces ¸ðµ¨Àº ¼¼°è ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå °æÀï ±¸µµ¸¦ Æò°¡Çϰí, ƯÁ¤ ºÎ¹®ÀÇ ¸Å·ÂÀ» ÃøÁ¤Çϰí, ÅõÀÚ ÀáÀç·ÂÀ» Æò°¡ÇÏ´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå ¼·Ð
- ½ÃÀåÀÇ Á¤ÀÇ
- ½ÃÀå ¼¼ºÐÈ
- Á¶»ç ½ºÄÉÁÙ
- ÀüÁ¦Á¶°Ç
- Á¦ÇÑ »çÇ×
Á¦2Àå VERIFIED MARKET RESEARCHÀÇ Á¶»ç ¹æ¹ý
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- µ¥ÀÌÅÍ »ï°¢Ãø·®
- º¸ÅÒ¾÷ Á¢±Ù
- Åé´Ù¿î Á¢±Ù
- Á¶»ç È帧
- »ê¾÷ Àü¹®°¡ÀÇ ÁÖ¿ä ÀλçÀÌÆ®
- µ¥ÀÌÅÍ ¼Ò½º
Á¦3Àå ÁÖ¿ä ¿ä¾à
- ½ÃÀå °³¿ä
- »ýÅÂ°è ¸ÅÇÎ
- Àý´ëÀû ¸ÅÃâ ±âȸ
- ½ÃÀåÀÇ ¸Å·Â
- ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå Áö¿ªº° ºÐ¼®
- ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå : ¿ë·®º°(100¸¸ ´Þ·¯)
- ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå : ¿ëµµº°(100¸¸ ´Þ·¯)
- ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°(100¸¸ ´Þ·¯)
- ÇâÈÄ ½ÃÀå ±âȸ
- ¼¼°è ½ÃÀå ³»¿ª
- Á¦Ç° ¶óÀÌÇÁ¶óÀÎ
Á¦4Àå ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå Àü¸Á
- ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ÁøÈ
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
- Porter's Five Forces ¸ðµ¨
- ¹ë·ùüÀÎ ºÐ¼®
- °¡°Ý ºÐ¼®
- °Å½Ã°æÁ¦ ºÐ¼®
Á¦5Àå ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå : ¿ë·®º°
- °³¿ä
- 100-250ml
- 250-500ml
- 500-1,000ml
- 1,000-2,000ml
- 2,000ml ÀÌ»ó
Á¦6Àå ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå : ¿ëµµº°
- °³¿ä
- Ä¡·á¿ë ÁÖ»ç
- ü¾× ¹ë·±½º ÁÖ»ç
- ¿µ¾ç ÁÖ»ç
Á¦7Àå ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°
Á¦8Àå ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå : Áö¿ªº°
- °³¿ä
- ºÏ¹Ì
- À¯·´
- µ¶ÀÏ
- ¿µ±¹
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå ¼¼°èÀÇ ´ë¿ë·® ºñ°æ±¸ ÀǾàǰ(LVP) ½ÃÀå °æÀï ±¸µµ
- °³¿ä
- ±â¾÷ÀÇ ½ÃÀå ¼øÀ§
- ±â¾÷ÀÇ Áö¿ªº° ½ÇÀû
- ±â¾÷ÀÇ »ê¾÷ ½ÇÀû
- ACE ¸ÅÆ®¸¯½º
Á¦10Àå ±â¾÷ °³¿ä
- B. Braun Melsungen AG
- Fresenius Kabi AG
- BML Parenteral Drugs
- Pfizer, Inc
- Otsuka Pharmaceutical
- Kelun Pharma
- Cook Pharma
- Patheon
- BAG Healthcare
- Southwest Pharmaceuticals
- Baxter Healthcare Corporation
Á¦11Àå VERIFIED MARKET INTELLIGENCE
- VERIFIED MARKET INTELLIGENCE¿¡ ´ëÇØ
- ´ÙÀ̳ª¹Í µ¥ÀÌÅÍ ½Ã°¢È
LSH
¿µ¹® ¸ñÂ÷
Large Volume Parenteral (LVP) Market Size And Forecast
Large Volume Parenteral (LVP) Market size was valued at USD 13.02 Billion in 2024 and is projected to reach USD 25.72 Billion by 2032, growing at a CAGR of 8.88% from 2026 to 2032.
The rising demand for safer, faster, and more effective methods for drug administration in patients leads to drive the market growth of the Global Large Volume Parenteral (LVP) Market. Also, patients now preferring to take administration for a single dose of vaccines or drugs to treat chronic diseases propels the market growth. The Global Large Volume Parenteral (LVP) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
Global Large Volume Parenteral (LVP) Market Definition
Parenterals are injectable preparations, sterile products which are intended for administration by way of injection, infusion, or implantation into the body. A large volume parenteral (LVP) is a unit dose container of greater than 100ml which is terminally sterilized by heat. These parenteral are included with intravenous solutions which are sold to be in bags or bottles containing 100ml or of greater sizes. If a large quantity is required then it is packaged in large volumes. When preparation of parental takes place parentals are sterile, solid dosage form or pyrogen-free liquids, which contain one or more active ingredients boxed in single or multi-dose containers.
Parenterals are meant to be administered by way of infusion, transplantation, or injection in the body. These are free of physical, chemical, and biological contamination. As the biotechnology field is developing there is a development in a certain number of drugs administered parenterally because the parenteral route is the best, when the oral route is not suitable. Maximum efficacy and bio-availability are provided by Parenterals and are preferred over oral dosages in a vast number of instances.
Global Large Volume Parenteral (LVP) Market Overview
The increase in health-related issues leads to the increasing hospitalization rate of people and due to this, there is a rise in demand for faster, safer, and effective administration of drugs which drives the growth of the Global Large Volume Parenteral (LVP) Market. Surgeries are increasing at a higher pace and because of this, there is an increase in the need for a faster route of drug administration and a growing preference for single-dose administration of vaccines and drugs.
Also, as the demand is increasing there is an increase in the local manufacturing which is expected to drive the market. The parental route helps in administering by providing an accurate dose of medication because the majority of the drug is directly absorbed in circulation, bypassing the gastrointestinal tract Parental route helps in administering and also drives the market growth. Patients with chronic and other lifestyle-related diseases are increasing and because of it, they were hospitalized.
The introduction of single-dosage nervous system disorders, oncology, and diabetes creates lucrative opportunities for the Global Large Volume Parenteral (LVP) Market. Also, patients are now preferring single-dose administration of vaccines and drugs to treat chronic diseases which drives the growth of the Global Large Volume Parenteral (LVP) Market. Increased demand in combination with manufacturing delays hampers the growth of the market. Also, LVPs quality issues and other manufacturing problems will result in a shortage of parenteral will restrain the market.
The Global Large Volume Parenteral (LVP) Market is segmented on the basis of Volume, Application, End-User, And Geography.
Large Volume Parenteral (LVP) Market, By Volume
100 ml - 250 ml
250 ml - 500 ml
500 ml - 1000 ml
1000 ml - 2000 ml
2000 ml and more
Based on Volume, The market is bifurcated into 100 ml - 250 ml, 250 ml - 500 ml, 500 ml - 1000 ml, 1000 ml - 2000 ml, and 2000 ml and more. In 2022, the 250 ml - 500 ml large volume parenteral (LVP) segment dominated the market. Large Volume Parenteral (LVP), often known as LVPs, are sterile preparations of 250 mL or higher that are delivered parenterally. For example, the most popular LVPs are IV solutions made from a standard/base solution, like 0.9% sodium chloride, dextrose 5% in normal saline (D5NS), dextrose 5% in water (D5W), and Lactate Ringer (L.R.) solution. LVPs are intravenous solutions offered in bags or bottles holding 100 mL or more (250 mL, 500 mL, 1 L).
Large Volume Parenteral (LVP) Market, By Application
- Therapeutic Injections
- Fluid Balance Injections
- Nutritious Injections
Based on Application, The market is bifurcated into Therapeutic Injections, Fluid Balance Injections, and Nutritious Injections. The nutritious injections by application segment are expected to dominate the Global Large Volume Parenteral (LVP) Market during the forecast period, owing to growing applications in the geriatric and pediatric populations, as well as its requirement in the management of chronic diseases such as ulcerative colitis and cancer. These patients require a continuous feeding system to compensate for nutritional inadequacies, paving the way for the segment.
Large Volume Parenteral (LVP) Market, By End-User
- Hospitals
- Medical Centers
- Others
Based on End-User, The market is bifurcated into Hospitals, Medical Centres, and Others. Hospitals and healthcare facilities will dominate the overall market for the Global Large Volume Parenteral (LVP) Market.
Large Volume Parenteral (LVP) Market, By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- On the basis of Regional Analysis, The Global Large Volume Parenteral (LVP) Market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America led the global market throughout the projection period due to its significant investment in healthcare research by public and private organizations, its technologically cutting-edge medical equipment, and its regulatory agencies and industry's close partnerships with universities.
- Additionally, favorable payment rules have increased hospital admissions, which is expected to enhance utilization rates in this area. For IV nutrition, the reimbursement picture is encouraging. Medicare provides patients with coverage for up to 80% of the costs associated with parenteral and enteral nourishment in the US, including the cost of medical supplies, doctor visits, and other related healthcare services.
Key Players
The "Global Large Volume Parenteral (LVP) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are B. Braun Melsungen AG, Fresenius Kabi AG, BML Parenteral Drugs, Pfizer, Inc, Otsuka Pharmaceutical, Kelun Pharma, Cook Pharma, Patheon, BAG Healthcare, Southwest Pharmaceuticals, Beximco Pharma, Baxter Healthcare Corporation.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
- Ace Matrix Analysis
- The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
- Ace Matrix Analysis of Large Volume Parenteral (LVP) Market
- Market Attractiveness
- The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Large Volume Parenteral (LVP) Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
- Geographical Representation of Large Volume Parenteral (LVP) Market
- Porter's Five Forces
- The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in the Global Large Volume Parenteral (LVP) Market, gauge the attractiveness of a certain sector, and assess investment possibilities.
TABLE OF CONTENTS
1 INTRODUCTION OF GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET
- 1.1 Market Definition
- 1.2 Market Segmentation
- 1.3 Research Timelines
- 1.4 Assumptions
- 1.5 Limitations
2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
- 2.1 Data Mining
- 2.2 Data Triangulation
- 2.3 Bottom-Up Approach
- 2.4 Top-Down Approach
- 2.5 Research Flow
- 2.6 Key Insights from Industry Experts
- 2.7 Data Sources
3 EXECUTIVE SUMMARY
- 3.1 Market Overview
- 3.2 Ecology Mapping
- 3.3 Absolute Market Opportunity
- 3.4 Market Attractiveness
- 3.5 Global Large Volume Parenteral (LVP) Market Geographical Analysis (CAGR %)
- 3.6 Global Large Volume Parenteral (LVP) Market, By Volume (USD Million)
- 3.7 Global Large Volume Parenteral (LVP) Market, By Application (USD Million)
- 3.8 Global Large Volume Parenteral (LVP) Market, By End User (USD Million)
- 3.9 Future Market Opportunities
- 3.10 Global Market Split
- 3.11 Product Life Line
4 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET OUTLOOK
- 4.1 Global Large Volume Parenteral (LVP) Evolution
- 4.2 Drivers
- 4.2.1 Driver1
- 4.2.2 Driver 2
- 4.3 Restraints
- 4.3.1 Restraint1
- 4.3.2 Restraint 2
- 4.4 Opportunities
- 4.4.1 Opportunity1
- 4.4.2 Opportunity 2
- 4.5 Porters Five Force Model
- 4.6 Value Chain Analysis
- 4.7 Pricing Analysis
- 4.8 Macroeconomic Analysis
5 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET, BY VOLUME
- 5.1 Overview
- 5.2100 ml - 250 ml
- 5.3 250 ml - 500 ml
- 5.4 500 ml -1000 ml
- 5.51000 ml - 2000 ml
- 5.6 2000 ml and more
6 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET, BY APPLICATION
- 6.1 Overview
- 6.2 Therapeutic Injections
- 6.3 Fluid Balance Injections
- 6.4 Nutritious Injections
7 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET, BY END-USER
- 7.1 Overview
- 7.2 Hospitals
- 7.3 Medical Centers
- 7.4 Others
8 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET, BY GEOGRAPHY
- 8.1 Overview
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
- 8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa
9 GLOBAL LARGE VOLUME PARENTERAL (LVP) MARKET COMPETITIVE LANDSCAPE
- 9.1 Overview
- 9.2 Company Market Ranking
- 9.3 Key Developments
- 9.4 Company Regional Footprint
- 9.5 Company Industry Footprint
- 9.6 ACE Matrix
10 COMPANY PROFILES
- 10.1 B. Braun Melsungen AG
- 10.1.1 Company Overview
- 10.1.2 Company Insights
- 10.1.3 Business Breakdown
- 10.1.4 Product Benchmarking
- 10.1.5 Key Developments
- 10.1.6 Winning Imperatives
- 10.1.7 Current Focus & Strategies
- 10.1.8 Threat from Competition
- 10.1.9 SWOT Analysis
- 10.2 Fresenius Kabi AG
- 10.2.1 Company Overview
- 10.2.2 Company Insights
- 10.2.3 Business Breakdown
- 10.2.4 Product Benchmarking
- 10.2.5 Key Developments
- 10.2.6 Winning Imperatives
- 10.2.7 Current Focus & Strategies
- 10.2.8 Threat from Competition
- 10.2.9 SWOT Analysis
- 10.3 BML Parenteral Drugs
- 10.3.1 Company Overview
- 10.3.2 Company Insights
- 10.3.3 Business Breakdown
- 10.3.4 Product Benchmarking
- 10.3.5 Key Developments
- 10.3.6 Winning Imperatives
- 10.3.7 Current Focus & Strategies
- 10.3.8 Threat from Competition
- 10.3.9 SWOT Analysis
- 10.4 Pfizer, Inc
- 10.4.1 Company Overview
- 10.4.2 Company Insights
- 10.4.3 Business Breakdown
- 10.4.4 Product Benchmarking
- 10.4.5 Key Developments
- 10.4.6 Winning Imperatives
- 10.4.7 Current Focus & Strategies
- 10.4.8 Threat from Competition
- 10.4.9 SWOT Analysis
- 10.5 Otsuka Pharmaceutical
- 10.5.1 Company Overview
- 10.5.2 Company Insights
- 10.5.3 Business Breakdown
- 10.5.4 Product Benchmarking
- 10.5.5 Key Developments
- 10.5.6 Winning Imperatives
- 10.5.7 Current Focus & Strategies
- 10.5.8 Threat from Competition
- 10.5.9 SWOT Analysis
- 10.6 Kelun Pharma
- 10.6.1 Company Overview
- 10.6.2 Company Insights
- 10.6.3 Business Breakdown
- 10.6.4 Product Benchmarking
- 10.6.5 Key Developments
- 10.6.6 Winning Imperatives
- 10.6.7 Current Focus & Strategies
- 10.6.8 Threat from Competition
- 10.6.9 SWOT Analysis
- 10.7 Cook Pharma
- 10.7.1 Company Overview
- 10.7.2 Company Insights
- 10.7.3 Business Breakdown
- 10.7.4 Product Benchmarking
- 10.7.5 Key Developments
- 10.7.6 Winning Imperatives
- 10.7.7 Current Focus & Strategies
- 10.7.8 Threat from Competition
- 10.7.9 SWOT Analysis
- 10.8 Patheon
- 10.8.1 Company Overview
- 10.8.2 Company Insights
- 10.8.3 Business Breakdown
- 10.8.4 Product Benchmarking
- 10.8.5 Key Developments
- 10.8.6 Winning Imperatives
- 10.8.7 Current Focus & Strategies
- 10.8.8 Threat from Competition
- 10.8.9 SWOT Analysis
- 10.9 BAG Healthcare
- 10.9.1 Company Overview
- 10.9.2 Company Insights
- 10.9.3 Business Breakdown
- 10.9.4 Product Benchmarking
- 10.9.5 Key Developments
- 10.9.6 Winning Imperatives
- 10.9.7 Current Focus & Strategies
- 10.9.8 Threat from Competition
- 10.9.9 SWOT Analysis
- 10.10 Southwest Pharmaceuticals
- 10.10.1 Company Overview
- 10.10.2 Company Insights
- 10.10.3 Business Breakdown
- 10.10.4 Product Benchmarking
- 10.10.5 Key Developments
- 10.10.6 Winning Imperatives
- 10.10.7 Current Focus & Strategies
- 10.10.8 Threat from Competition
- 10.10.9 SWOT Analysis
- 10.11 Baxter Healthcare Corporation.
- 10.11.1 Company Overview
- 10.11.2 Company Insights
- 10.11.3 Business Breakdown
- 10.11.4 Product Benchmarking
- 10.11.5 Key Developments
- 10.11.6 Winning Imperatives
- 10.11.7 Current Focus & Strategies
- 10.11.8 Threat from Competition
- 10.11.9 SWOT Analysis
11 VERIFIED MARKET INTELLIGENCE
- 11.1 About Verified Market Intelligence
- 11.2 Dynamic Data Visualization
°ü·ÃÀÚ·á